O varian cancers will account for over 14 000 estimated deaths in the United States in 2015, with nearly twothirds presenting at high stage with a poor 5-year overall survival rate (27% 6, 9 indicating that this alteration is an early event in the oncogenesis of HGSC. However, comprehensive sequencing-based assessment of molecular alterations in TICs has not been reported in large part owing to their minute size. Likewise, it is unclear if some presumed STICs may in fact represent metastatic tubal deposits. To more comprehensively assess somatic alterations in TICs and assess associations between TICs and synchronous carcinomas, we performed a pilot study of targeted nextgeneration sequencing (NGS) on a series of 4 TICs (2 discovered incidentally) in patients undergoing total abdominal hysterectomy/bilateral salpingo-oophorectomy (TAH/BSO) for gynecologic malignant neoplasms.
O varian cancers will account for over 14 000 estimated deaths in the United States in 2015, with nearly twothirds presenting at high stage with a poor 5-year overall survival rate (27%). 1 Despite advances in surgery, medicine, and imaging, ovarian cancer mortality has changed little over several decades, and the need for early detection of cancers at a curable stage remains unmet. A dualistic model of ovarian cancer pathogenesis posits a heterogeneous group of low-grade, clinically indolent, genomically stable tumors (type I, which account for approximately 25% of all ovarian carcinomas) and a high-grade, clinically aggressive group with high risk for distant metastases (type II, comprising the remaining carcinomas, roughly 75%). [2] [3] [4] These groups can also be broadly distinguished on morphologic grounds, with high-grade serous carcinoma (HGSC) comprising most type II cancers, the most common and lethal ovarian carcinoma group. In contrast to type I ovarian carcinomas, 3, 4 type II tumors are characterized by very frequent TP53 mutations (>95%) 5 and associated genomic instability.
Many, if not most, ovarian HGSCs are derived from precursor lesions arising from epithelium in the fimbriated end of the fallopian tube. [6] [7] [8] These precursor lesions, termed serous tubal intraepithelial carcinomas (TICs and, more specifically, STICs), demonstrate atypical histologic changes that are reminiscent of HGSC. Furthermore, STICs harbor clonal TP53 mutations, 6, 9 indicating that this alteration is an early event in the oncogenesis of HGSC. However, comprehensive sequencing-based assessment of molecular alterations in TICs has not been reported in large part owing to their minute size. Likewise, it is unclear if some presumed STICs may in fact represent metastatic tubal deposits. To more comprehensively assess somatic alterations in TICs and assess associations between TICs and synchronous carcinomas, we performed a pilot study of targeted nextgeneration sequencing (NGS) on a series of 4 TICs (2 discovered incidentally) in patients undergoing total abdominal hysterectomy/bilateral salpingo-oophorectomy (TAH/BSO) for gynecologic malignant neoplasms.
Methods

Tissue Samples
Four cases of gynecologic malignant neoplasms diagnosed in 2011 to 2012 with coexisting TIC were selected from the case IMPORTANCE High-grade serous carcinoma (HGSC) is the most prevalent and lethal form of ovarian cancer. HGSCs frequently arise in the distal fallopian tubes rather than the ovary, developing from small precursor lesions called serous tubal intraepithelial carcinomas (TICs, or more specifically, STICs). While STICs have been reported to harbor TP53 mutations, detailed molecular characterizations of these lesions are lacking.
OBSERVATIONS We performed targeted next-generation sequencing (NGS) on formalin-fixed, paraffin-embedded tissue from 4 women, 2 with HGSC and 2 with uterine endometrioid carcinoma (UEC) who were diagnosed as having synchronous STICs. We detected concordant mutations in both HGSCs with synchronous STICs, including TP53 mutations as well as assumed germline BRCA1/2 alterations, confirming a clonal association between these lesions. Next-generation sequencing confirmed the presence of a STIC clonally unrelated to 1 case of UEC, and NGS of the other tubal lesion diagnosed as a STIC unexpectedly supported the lesion as a micrometastasis from the associated UEC.
CONCLUSIONS AND RELEVANCE We demonstrate that targeted NGS can identify genetic alterations in minute lesions, such as TICs, and confirm TP53 mutations as early driving events for HGSC. Next-generation sequencing also demonstrated unexpected associations between presumed STICs and synchronous carcinomas, providing evidence that some TICs are actually metastases rather than HGSC precursors.
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Immunohistochemical Analysis
Immunohistochemical (IHC) analysis was performed using the Ventana Benchmark System (Ventana Medical Systems) on formalin-fixed, paraffin-embedded (FFPE) tissue sections cut to a thickness of 4 μm. Antibody clones and staining evaluation are described in the eMethods in the Supplement.
Targeted NGS
Ten-micron FFPE sections (10 per sample) were cut from representative blocks from the primary tumor and the tubal lesion from each case. Tumor tissue containing high estimated tumor content (ranging from 60% to 80% tumor nuclei) was macrodissected. DNA isolation, NGS using the DNA component of the Oncomine Comprehensive Panel (OCP), and data analysis to identify prioritized nonsynonymous mutations were performed essentially as described. 10, 11 We have extensively validated this OCP workflow performance using molecular standards and routine tissue samples, 11 and detailed information is provided in the eMethods in the Supplement.
Results
Clinicopathologic Characteristics
We identified 4 cases from 2011 to 2012 in which TICs (all presumed to be serous) were identified in TAH/BSO specimens resected for gynecologic cancer ( Table 1 
NGS Results
Manual macrodissection was used to isolate TICs and matched invasive carcinomas from each case (eFigure 1 in the Supplement). Targeted NGS was performed on 5 to 20 ng of genomic DNA, using a custom, multiplexed polymerase chain reactionbased Ion Torrent Ampliseq panel comprising 2462 amplicons covering 135 cancer-related genes (the DNA component of the OCP; the genes are in the eTable in the Supplement) with sequencing performed on the IonTorrent PGM Sequencer. Detailed information on DNA yield and sequencing statistics, including germline single nucleotide polymorphism concor-
At a Glance
• Serous tubal intraepithelial carcinomas (STICs) are precursors of the most common type of ovarian cancer, but detailed genomic characterization of these microscopic lesions has been lacking. • Targeted next-generation sequencing on 4 tubal intraepithelial carcinomas (TICs) from patients with concurrent ovarian or uterine cancers was performed.
• TP53 mutations were present in all TICs • In patients with ovarian cancer, concordant mutations in TP53
and BRCA1/2 in the STIC and paired cancer confirm clonal associations between these lesions. • Some TICs are actually mucosal metastases from carcinomas arising outside of the fallopian tube, as shown in a patient with uterine cancer. . White arrowhead shows low staining in the normal epithelium (original magnification ×400). E, IHC staining for PAX8 in the TIC (black arrowhead) shows strong nuclear reactivity. White arrowhead indicates normal epithelium (original magnification ×400). F, IHC staining for WT-1 in the TIC (black arrowhead) shows absent nuclear expression. White arrowhead indicates WT expression in normal epithelium (original magnification ×400). G, Low-power photomicrograph of patient 4's primary UEC (hematoxylin-eosin, original magnification ×40). H, High-power photomicrograph of the area indicated by the rectangle in panel G (hematoxylin-eosin, original magnification ×400). I, IHC for p53 in the primary UEC shows a WT staining pattern (original magnification ×400). J, IHC staining for Ki-67 in the primary UEC shows a mitotic index of approximately 20% (original magnification ×400). K, IHC staining for PAX8 in the primary UEC shows patchy nuclear positivity (original magnification ×400). L, IHC staining for WT-1 in the primary UEC shows absent nuclear expression. Next-generation sequencing detected the presence of a TP53 mutation exclusively in the tubal lesion from patient 4, consistent with IHC results (compare panels C and I), supporting the tubal lesion from patient 4 as a mucosal micrometastasis/implant from the patient's primary UEC rather than a STIC (original magnification ×400).
dance in paired cases (≥92% per paired sample), is provided in Table 1 and eFigure 2, the eResults, and the eReferences in the Supplement. The NGS variant calls were filtered using predefined criteria (see the eMethods in the Supplement) to nominate potential somatic driving alterations. Somatic TP53 mutations were present in all 4 tubal lesions ( Table 2) , with the 2 patients with HGSC showing evidence of a clonal association between the TICs and the primary serous ovarian carcinomas (details are provided in the eMethods in the Supplement). For the 2 patients who presented with incidental TICs in the context of UEC, NGS demonstrated that the 2 lesions in patient 3 were genetically heterogeneous, with the TIC harboring a single TP53 mutation and the UEC showing somatic MTOR, PTEN, KRAS, PIK3CA, and ATM mutations (Table 2) , consistent with a genetically distinct STIC and UEC. In patient 4, who harbored a TIC and a UEC (histologic images are shown in the Figure, B, G, and H) , the tubal lesion surprisingly demonstrated somatic PTEN and CTNNB1 mutations in addition to a TP53 mutation; the matched UEC also demonstrated concordant PTEN and CTNNB1 mutations, but no TP53 mutation was noted (despite >200 covering reads at that position). Correspondingly, IHC for p53 showed a clonal staining pattern in the TIC, with wild-type (WT) staining observed in the primary tumor ( Figure C vs I) . Additional IHC stains (Figure, D-F and J-L) demonstrate both the primary tumor and TIC to be positive for PAX8 and negative for WT-1. The TIC showed a proliferative index around 40% (as assessed by Ki-67 IHC), while the primary tumor demonstrated 20% to 30% Ki-67 staining. As described in the next section, this genomic profile and immunophenotype supports the tubal lesion as a micrometastasis (tube mucosal implant) from the UEC rather than a STIC.
Discussion
Herein, we report using targeted NGS on macrodissected routine FFPE archival tissue for a comprehensive investigation of somatic driving mutations associated with fallopian tube TICs and their association with synchronous gynecologic malignant neoplasms. In all tubal lesions, somatic TP53 mutations were identified, consistent with findings of previous reports that TP53 mutation occurs early in the pathogenesis of HGSC. 9 and the common use of TP53 immunostaining in STIC diagnosis. The genetic concordance between the STICs and HGSCs in patients 1 and 2 supports a clonal association between the 2 lesions. In contrast, the mutational discordance between the STIC and UEC in patient 3 implies separate and independent neoplastic processes in the fallopian tube and uterus. Patients 1 and 2 harbored germline BRCA1/2 mutations, and STICs are frequently found in the fallopian tubes of patients with germline BRCA mutation with concomitant HGSC and in approximately 5% of those undergoing prophylactic TAH/BSO for HGSC risk-reduction. 12 The STIC in patient 3 is potentially sporadic because no germline cancer predisposing mutations in BRCA1, BRCA2, or MSH2 were identified; however, additional cancer predisposing loci were not assessed because the OCP was designed to interrogate somatic driving alterations. 
